Recent reports [35,36,37] have suggested that the overexpression of HO-1 may promote the progression and relapse of various blood cancers, especially CML, as well as carcinogenesis, progression, and resistance to therapy in solid cancers. Here, HMOX1 is linked to hematopoietic and lymphoid system neoplasm.